ArticleScientific reports2017
Stigmasterol prevents glucolipotoxicity induced defects in glucose-stimulated insulin secretion.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Evaluating efficacy and mechanism of traditional Chinese medicine in diabetes treatment: a meta-analysis and network pharmacology study.Frontiers in endocrinology · 2025Pooled it
- GenusInternational journal of molecular sciences · 2021Pooled it
- Exploring the mechanism of stigmasterol against androgenetic alopecia using geometry optimization, network pharmacology, molecular docking, and molecular dynamics studies.Scientific reports · 2026Article
- Stigmasterol restores testicular and sperm function in ICR mice exposed to high oxidative stress condition.Die Naturwissenschaften · 2026Article
- Phytosterols: Extraction Methods, Analytical Techniques, and Biological Activity.Molecules (Basel, Switzerland) · 2025Review
- Elucidating the Mechanism of Jisheng Shenqi Pills in the Treatment of Diabetic Kidney Disease: Network Pharmacology Combined with Experimental Verification.Endocrine, metabolic & immune disorders drug targets · 2025Article
- Article
- Phytosome Supplements for DeliveringFoods (Basel, Switzerland) · 2023Article
- Anti-Glucotoxicity Effect of PhytoconstituentsInternational journal of molecular sciences · 2023Review
- Effect of Distigmasterol-Modified Acylglycerols on the Fluidity and Phase Transition of Lipid Model Membranes.Membranes · 2022Article
- An automatic hypothesis generation for plausible linkage between xanthium and diabetes.Scientific reports · 2022Article
- Health Benefits and Pharmacological Properties of Stigmasterol.Antioxidants (Basel, Switzerland) · 2022Review
- Network pharmacology-based strategy for predicting therapy targets of Sanqi and Huangjing in diabetes mellitus.World journal of clinical cases · 2022Article
- Acylglycerols of Myristic Acid as New Candidates for Effective Stigmasterol Delivery-Design, Synthesis, and the Influence on Physicochemical Properties of Liposomes.Molecules (Basel, Switzerland) · 2022Article
- Advances in Stigmasterol on its anti-tumor effect and mechanism of action.Frontiers in oncology · 2022Review
- Effects ofJournal of food science and technology · 2021Article
- Mechanisms and Neuroprotective Activities of Stigmasterol Against Oxidative Stress-Induced Neuronal Cell DeathFrontiers in nutrition · 2021Article
- Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism.Drug design, development and therapy · 2021Article
- Phytosterols: Nutritional Health Players in the Management of Obesity and Its Related Disorders.Antioxidants (Basel, Switzerland) · 2020Review
- Dietary Supplementation with Chestnut (Castanea sativa) Reduces Abdominal Adiposity in FVB/n Mice: A Preliminary Study.Biomedicines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Type 2 diabetes results from defects in both insulin sensitivity and insulin secretion. Elevated cholesterol content within pancreatic β-cells has been shown to reduce β-cell function and increase β-cell apoptosis. Hyperglycemia and dyslipidemia contribute to glucolipotoxicity that leads to type 2 diabetes. Here we examined the capacity of glucolipotoxicity to induce free cholesterol accumulation in human pancreatic islets and the INS-1 insulinoma cell line. Glucolipotoxicity treatment increased free cholesterol in β-cells, which was accompanied by increased reactive oxygen species (ROS) production and decreased insulin secretion. Addition of AAPH, a free radical generator, was able to increase filipin staining indicating a link between ROS production and increased cholesterol in β-cells. We also showed the ability of stigmasterol, a common food-derived phytosterol with anti-atherosclerotic potential, to prevent the increase in both free cholesterol and ROS levels induced by glucolipotoxicity in INS-1 cells. Stigmasterol addition also inhibited early apoptosis, increased total insulin, promoted actin reorganization, and improved insulin secretion in cells exposed to glucolipotoxicity. Overall, these data indicate cholesterol accumulation as an underlying mechanism for glucolipotoxicity-induced defects in insulin secretion and stigmasterol treatment as a potential strategy to protect β-cell function during diabetes progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.